Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch
- 1 April 2009
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 49 (4) , 430-443
- https://doi.org/10.1177/0091270008330161
Abstract
The pharmacokinetics and pharmacodynamics of rivastigmine were compared in Japanese and white healthy participants who were given ascending single doses of the novel rivastigmine transdermal patch. Rivastigmine patch strengths were 4.6 mg/24 h (5 cm2, 9 mg rivastigmine loaded dose), 9.5 mg/24 h (10 cm2, 18 mg), and 13.3 mg/24 h (15 cm2, 27 mg) (per label) or 7.0 mg/24 h (7.5 cm2, 13.5 mg) as a fall-back dose. No relevant ethnic differences in the noncompartmental pharmacokinetics (parent and metabolite NAP226-90) and pharmacodynamics (plasma BuChE activity) of the rivastigmine patch were observed between Japanese and whites. However, drug exposure was slightly higher and inhibition of BuChE slightly more pronounced in Japanese participants than in whites, which was attributed to the lower body weight (ca. 11% less on average) of Japanese participants. Treatments were similarly well tolerated in both ethnic groups. In conclusion, no relevant ethnic differences in the intrinsic disposition or effects of rivastigmine delivered via transdermal route are expected between Japanese and white patients. The possible effect of body weight on drug exposure suggests that special attention should be paid to patients with very low body weight during up-titration.Keywords
This publication has 20 references indexed in Scilit:
- Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease PatientsClinical Pharmacology & Therapeutics, 2007
- A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsuleInternational Journal of Geriatric Psychiatry, 2007
- Rivastigmine exposure provided by a transdermal patch versus capsulesCurrent Medical Research and Opinion, 2007
- Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefitJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2002
- Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase InhibitorsClinical Pharmacokinetics, 2002
- β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High AffinityJournal of Biological Chemistry, 2000
- Cholinesterase Inhibitors in the Treatment of Alzheimer??s DiseaseDrug Safety, 1998
- Diagnosis and Treatment of Alzheimer Disease and Related DisordersJAMA, 1997
- Practice guideline for the treatment of patients with schizophrenia. American Psychiatric AssociationAmerican Journal of Psychiatry, 1997
- A new and rapid colorimetric determination of acetylcholinesterase activityBiochemical Pharmacology, 1961